Development and validation of a scoring index to predict the presence of lesions in capsule endoscopy in patients with suspected Crohn’s disease of the small bowel

Autor: Pilar Borque Barrera, Marisol Luján-Sanchis, Begoña Gonzalez Suarez, Vicente Pons Beltrán, Joaquín Sánchez Cuenca, César Prieto de Frías, Fernando Alberca de Las Parras, José Francisco Juanmartiñena Fernández, Enrique Pérez-Cuadrado Robles, Julio Valle Muñoz, Noelia Alonso Lázaro, Blanca Martínez Andrés, Fernando Carballo Álvarez, Cristian Sierra Bernal, Violeta María Sastre Lozano, Carolina Torres González, Cristina Rodríguez de Miguel, Juan Egea-Valenzuela, Ignacio Fernández-Urién Sainz, Cristina Carretero Ribón, Mileidis San Juan Acosta, Félix de Vera Almenar, Pilar Martínez García
Rok vydání: 2018
Předmět:
Male
capsule endoscopy
Disease
Capsule Endoscopy
law.invention
Feces
0302 clinical medicine
Crohn Disease
law
small bowel
Intestine
Small

Medicine
030212 general & internal medicine
Young adult
Child
Aged
80 and over

education.field_of_study
Crohn's disease
Gastroenterology
Middle Aged
C-Reactive Protein
Child
Preschool

Predictive value of tests
Biomarker (medicine)
Female
030211 gastroenterology & hepatology
Adult
medicine.medical_specialty
Adolescent
Population
Risk Assessment
Sensitivity and Specificity
Young Adult
03 medical and health sciences
Predictive Value of Tests
Capsule endoscopy
Internal medicine
Humans
education
Aged
Hepatology
business.industry
biomarkers
Reproducibility of Results
medicine.disease
digestive system diseases
Calprotectin
business
Leukocyte L1 Antigen Complex
Biomarkers
Zdroj: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
ISSN: 0954-691X
DOI: 10.1097/meg.0000000000001083
Popis: Background Capsule endoscopy (CE) is the first-line investigation in cases of suspected Crohn's disease (CD) of the small bowel, but the factors associated with a higher diagnostic yield remain unclear. Objective Our aim is to develop and validate a scoring index to assess the risk of the patients in this setting on the basis of biomarkers. Patients and methods Data on fecal calprotectin, C-reactive protein, and other biomarkers from a population of 124 patients with suspected CD of the small bowel studied by CE and included in a PhD study were used to build a scoring index. This was first used on this population (internal validation process) and after that on a different set of patients from a multicenter study (external validation process). Results An index was designed in which every biomarker is assigned a score. Three risk groups have been established (low, intermediate, and high). In the internal validation analysis (124 individuals), patients had a 10, 46.5, and 81% probability of showing inflammatory lesions in CE in the low-risk, intermediate-risk, and high-risk groups, respectively. In the external validation analysis, including 410 patients from 12 Spanish hospitals, this probability was 15.8, 49.7, and 80.6% for the low-risk, intermediate-risk, and high-risk groups, respectively. Conclusion Results from the internal validation process show that the scoring index is coherent, and results from the external validation process confirm its reliability. This index can be a useful tool for selecting patients before CE studies in cases of suspected CD of the small bowel.
Databáze: OpenAIRE